vs
Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Creative Media & Community Trust Corp is the larger business by last-quarter revenue ($28.5M vs $28.1M, roughly 1.0× ARS Pharmaceuticals, Inc.). Creative Media & Community Trust Corp runs the higher net margin — -125.8% vs -147.1%, a 21.4% gap on every dollar of revenue. On growth, Creative Media & Community Trust Corp posted the faster year-over-year revenue change (3.6% vs -67.6%).
Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CMCT vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.5M | $28.1M |
| Net Profit | $-11.4M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -125.6% | -147.6% |
| Net Margin | -125.8% | -147.1% |
| Revenue YoY | 3.6% | -67.6% |
| Net Profit YoY | -11.4% | -182.8% |
| EPS (diluted) | $-3.89 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.5M | $28.1M | ||
| Q3 25 | $26.2M | $32.5M | ||
| Q2 25 | $29.7M | $15.7M | ||
| Q1 25 | $32.3M | $8.0M | ||
| Q4 24 | $27.5M | $86.6M | ||
| Q3 24 | $28.6M | $2.1M | ||
| Q2 24 | $34.4M | $500.0K | ||
| Q1 24 | $34.0M | $0 |
| Q4 25 | $-11.4M | $-41.3M | ||
| Q3 25 | $-12.5M | $-51.2M | ||
| Q2 25 | $-9.0M | $-44.9M | ||
| Q1 25 | $-6.1M | $-33.9M | ||
| Q4 24 | $-10.3M | $49.9M | ||
| Q3 24 | $-10.4M | $-19.1M | ||
| Q2 24 | $-796.0K | $-12.5M | ||
| Q1 24 | $-3.7M | $-10.3M |
| Q4 25 | -125.6% | -147.6% | ||
| Q3 25 | -47.7% | -163.7% | ||
| Q2 25 | -30.3% | -302.9% | ||
| Q1 25 | -19.0% | -466.3% | ||
| Q4 24 | -128.8% | 54.5% | ||
| Q3 24 | -36.9% | -1051.6% | ||
| Q2 24 | -1.6% | -3068.0% | ||
| Q1 24 | -10.7% | — |
| Q4 25 | -125.8% | -147.1% | ||
| Q3 25 | -47.5% | -157.4% | ||
| Q2 25 | -30.3% | -285.6% | ||
| Q1 25 | -18.9% | -425.7% | ||
| Q4 24 | -129.8% | 57.7% | ||
| Q3 24 | -36.3% | -925.0% | ||
| Q2 24 | -2.3% | -2503.2% | ||
| Q1 24 | -11.0% | — |
| Q4 25 | $-3.89 | $-0.41 | ||
| Q3 25 | $-23.52 | $-0.52 | ||
| Q2 25 | $-18.94 | $-0.46 | ||
| Q1 25 | $-20.73 | $-0.35 | ||
| Q4 24 | $97.71 | $0.52 | ||
| Q3 24 | $-305.04 | $-0.20 | ||
| Q2 24 | $-98.64 | $-0.13 | ||
| Q1 24 | $-125.46 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.4M | $245.0M |
| Total DebtLower is stronger | $509.8M | $96.4M |
| Stockholders' EquityBook value | $265.4M | $114.3M |
| Total Assets | $859.2M | $327.7M |
| Debt / EquityLower = less leverage | 1.92× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.4M | $245.0M | ||
| Q3 25 | $17.3M | $288.2M | ||
| Q2 25 | $27.8M | $240.1M | ||
| Q1 25 | $19.8M | $275.7M | ||
| Q4 24 | $20.3M | $314.0M | ||
| Q3 24 | $18.5M | $204.6M | ||
| Q2 24 | $29.3M | $218.7M | ||
| Q1 24 | $21.3M | $223.6M |
| Q4 25 | $509.8M | $96.4M | ||
| Q3 25 | $527.8M | $96.2M | ||
| Q2 25 | $535.6M | — | ||
| Q1 25 | $512.7M | — | ||
| Q4 24 | $505.7M | $0 | ||
| Q3 24 | $478.3M | — | ||
| Q2 24 | $485.1M | — | ||
| Q1 24 | $472.8M | — |
| Q4 25 | $265.4M | $114.3M | ||
| Q3 25 | $281.9M | $147.7M | ||
| Q2 25 | $287.1M | $192.3M | ||
| Q1 25 | $293.0M | $229.0M | ||
| Q4 24 | $304.5M | $256.8M | ||
| Q3 24 | $321.0M | $201.0M | ||
| Q2 24 | $351.1M | $215.2M | ||
| Q1 24 | $369.9M | $223.9M |
| Q4 25 | $859.2M | $327.7M | ||
| Q3 25 | $871.8M | $372.8M | ||
| Q2 25 | $885.0M | $313.5M | ||
| Q1 25 | $882.3M | $327.3M | ||
| Q4 24 | $889.6M | $351.2M | ||
| Q3 24 | $868.0M | $217.6M | ||
| Q2 24 | $891.2M | $222.0M | ||
| Q1 24 | $887.5M | $227.6M |
| Q4 25 | 1.92× | 0.84× | ||
| Q3 25 | 1.87× | 0.65× | ||
| Q2 25 | 1.87× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 1.66× | 0.00× | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.38× | — | ||
| Q1 24 | 1.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.8M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | $-43.5M | ||
| Q3 25 | $3.7M | $-47.0M | ||
| Q2 25 | $-2.5M | $-39.6M | ||
| Q1 25 | $1.2M | $-40.7M | ||
| Q4 24 | $17.0M | $42.0M | ||
| Q3 24 | $10.3M | $-14.5M | ||
| Q2 24 | $3.9M | $-7.3M | ||
| Q1 24 | $1.6M | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCT
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
